skip to primary navigationskip to content
 

Potential target for lung cancer treatment discovered

last modified Aug 21, 2018 09:24 AM
Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications today...

https://crukcambridgecentre.org.uk/news/potential-target-lung-cancer-treatment-discovered

Cancer Research UK-funded scientists, based at the University of Cambridge, found lung squamous cell carcinoma (LUSC) cells contained high amounts of a protein called BCL11A. The study showed that manipulating the gene responsible for the protein stopped the development of LUSC in a mouse model of the disease.

The study also revealed a signalling pathway that BCL11A was involved in, and found a potential druggable target, called SETD8. Targeting this molecule both genetically and with early forms of drugs, selectively targeted LUSC cancer cells growing in the lab, and in LUSC cells transplanted into mice.

These early discoveries have led to further funding being granted by Cancer Research UK to facilitate the development of a drug to target the protein, which could one day lead to a new treatment option for some people with lung cancer.

Dr Kyren Lazarus, study author from the University of Cambridge and member of the CRUK Cambridge Centre Cell and Molecular Biology Programme said: “How LUSC develops is a bit of puzzle – until now our molecular understanding of this process was limited. “Our research has revealed a major piece of this puzzle, which we are now actively trying to make new drugs against.”

Over the last 40 years, lung cancer survival has remained stubbornly low, particularly when compared to overall cancer survival which has more than doubled. One of the reasons for this is the lack of targeted treatments for lung cancer, and currently just 5 in 100 people survive their disease for 10 or more years.

Dr Walid Khaled, lead author from the University of Cambridge and member of the CRUK Cambridge Centre said: “Developing targeted treatments is a real opportunity for improving the outlook for patients.

“With this new drug discovery grant from Cancer Research UK we are working to develop small molecules to specifically block BCL11A in LUSC cells. We are aiming to disrupt critical interactions that BCL11A has with other proteins and are working closely with our colleagues at the Department of Biochemistry in Cambridge and CRUK Beatson Institute Drug Discovery Unit to achieve this.”

Professor Karen Vousden, Cancer Research UK’s chief scientist, said: “Identifying potentially druggable targets is an early yet crucial stage in the journey towards precision medicine.
“While there is much to be done before this work could be translated into patient benefit, it’s a fundamental step towards that goal and we look forward to seeing how this discovery progresses along the research pipeline.”

Reference:
Kyren A Lazarus et al. BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma Nature Communications 9, 3327 (2018).

« September 2019 »
September
MoTuWeThFrSaSu
1
2345678
9101112131415
16171819202122
23242526272829
30

RSS Feed Latest news

Annual David James Lecture

Sep 02, 2019

Title: Human Pain Channelopathies

Pharmacology Lunch-time Run Club

Aug 23, 2019

The Pharmacology Lunch-time Run Club has been going strong since September 2018! We would love to see new faces, so if anyone is interested please join us...

Study led by Gates Cambridge PhD Student Sampurna Chakrabarti

Aug 15, 2019

The group of Dr Ewan St. John Smith have demonstrated that the fluid which lubricates joints plays a key role in osteoarthritic pain...

Congratulations Kerry!

Aug 14, 2019

On being awarded a BBSRC Flexible Talent Mobility Award to attend the Project in Drug Discover 2019 event, "Looking Back to the Future" in November.

View all news